Crohn's disease is a relapsing systemic inflammatory disease, mainly affecting the
gastrointestinal tract with extraintestinal manifestations and associated immune disorders …

Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders. In
this paper we discuss the current diagnostic approach, their pathology, natural course, and …

Ulcerative colitis (UC) is a common gastrointestinal disorder in adults. Recent advances in
pathophysiology, immunology, and pharmaceutical science have resulted in a large number …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis
factor α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods …

Background The comparative efficacy and safety of infliximab and azathioprine therapy
alone or in combination for Crohn's disease are unknown. Methods In this randomized …

Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully
human, anti–tumor necrosis factor monoclonal antibody administered subcutaneously, in the …

Background Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and
interleukin-23, was evaluated as an intravenous induction therapy in two populations with …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized …

Background The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials …